When did Xeris Biopharma Holdings, Inc. report Q4 2024 earnings?

Xeris Biopharma Holdings, Inc. (XERS) reported Q4 2024 earnings on March 6, 2025 before market open.

What were Xeris Biopharma Holdings, Inc.'s Q4 2024 revenue and EPS?

Xeris Biopharma Holdings, Inc. reported revenue of $60.1M and eps of $-0.03 for Q4 2024.

Did Xeris Biopharma Holdings, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $54.9M by $5.2M. EPS beat the consensus estimate of $-0.08 by $0.05.

Where can I find Xeris Biopharma Holdings, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001867096-25-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.

Xeris Biopharma Holdings, Inc. XERS Q4 2024 Annual earnings

Reported March 6, 2025 · Before market open

Revenue$60.1MBeat by $5.2M

EPS-$0.03Beat by $0.05

Revenue estimate$54.9M

EPS estimate-$0.08

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$90.1M

EPS estimate$0.02

Financials

Q4 2024

Income statement

See full

Revenue$60.1M+35.4%

Gross profit$50.6M+37.5%

Operating income-+100%

Net income-$5.1M+61.8%

EPS (diluted)-$0.03+66.7%

Balance sheet

See full

Cash & equivalents$71.6M+6.2%

Total debt$271.4M+18.4%

Total equity-$29.6M-337%

Total assets$323.1M+0.1%

Cash flow

See full

Operating cash flow-—

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$505.39M+55.7%

Enterprise value$705.21M+45.0%

P/S2.5×+0.5×

Profitability

See full

Gross margin81.9%-0.7pp

Operating margin-17.4%-4.5pp

Net margin-27%-6.1pp

Returns & leverage

See full

Current ratio1.7×0.0×

Segments

By product

See full

Gvoke$23.3M+24.8%

Recorlev$22.6M+131%

Keveyis$11.1M-20.9%

Royalty, contract and other revenue$3.1M+64.8%

Versus estimates

Revenue

Q1 2026$82.5MBeat by $2.6M Q4 2025$85.8MBeat by $3.6M Q3 2025$74.4MMiss by $11.6M Q2 2025$71.5MMiss by $711.0K Q1 2025$60.1MBeat by $2.5M

Q4 2024$60.1MBeat by $5.2M

Diluted EPS

Q1 2026$0.01Beat by $0.01 Q4 2025$0.06Beat by $0.03 Q3 2025$0.00Miss by $0.01 Q2 2025-$0.01Beat by $0.02 Q1 2025-$0.06Beat by $0.01

Q4 2024-$0.03Beat by $0.05

Ask the moment Xeris Biopharma Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Xeris Biopharma Holdings, Inc. report Q4 2024 earnings?: Xeris Biopharma Holdings, Inc. (XERS) reported Q4 2024 earnings on March 6, 2025 before market open.
What were Xeris Biopharma Holdings, Inc.'s Q4 2024 revenue and EPS?: Xeris Biopharma Holdings, Inc. reported revenue of $60.1M and eps of $-0.03 for Q4 2024.
Did Xeris Biopharma Holdings, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $54.9M by $5.2M. EPS beat the consensus estimate of $-0.08 by $0.05.
Where can I find Xeris Biopharma Holdings, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001867096-25-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.